Phase I study of the heparanase inhibitor roneparstat: an innovative approach for ultiple myeloma therapy

Haematologica. 2018 Oct;103(10):e469-e472. doi: 10.3324/haematol.2017.182865. Epub 2018 Apr 26.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter

MeSH terms

  • Aged
  • Aged, 80 and over
  • Enzyme Inhibitors / administration & dosage*
  • Enzyme Inhibitors / adverse effects
  • Female
  • Heparin / administration & dosage
  • Heparin / adverse effects
  • Heparin / analogs & derivatives*
  • Heparin Lyase / antagonists & inhibitors*
  • Heparin Lyase / metabolism
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / enzymology
  • Neoplasm Proteins / antagonists & inhibitors*
  • Neoplasm Proteins / metabolism

Substances

  • Enzyme Inhibitors
  • Neoplasm Proteins
  • SST 0001
  • Heparin
  • Heparin Lyase